drugset / Trial / NCT00806260

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

NCT00806260

Phase 2 Completed 80 enrolled VIVUS LLC MDS Pharma Services · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine how VI-0521 affect speed and reaction time on specific tasks that require eye and hand coordination, compared to placebo.

Timeline

Start
2008-12
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentermine Small molecule 15 mg
Subject Topiramate Small molecule 92 mg

Indications